nach oben

Inflammation

Erschienen in:

08.01.2020 | Original Article

Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition

verfasst von: Guofan Chen, Xiaozheng Song, Dongming Lin, Peng Xu

Erschienen in: Inflammation | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Isofraxidin is a well-known coumarin compound refined from traditional Chinese medicines. It has been previously demonstrated to play an anti-inflammatory role in various inflammatory conditions. However, the effect of isofraxidin on myocardial infarction (MI) remains uncovered. In this study, we aimed to investigate the effect of isofraxidin on MI. MI mice was created and triphenyltetrazolium chloride (TTC) staining as well as echocardiographic evaluation were conducted to analyze the severity of MI. Oxygen-glucose deprivation (OGD) was used for the mimics of ischemic stress in murine cardiomyocytes, and Cell Counting Kit-8 (CCK-8), Annexin V, and lactate dehydrogenase (LDH) release assays were conducted for cell viability. Western blot was used for the detection of NOD-like receptor family, pyrin domain containing 3 (NLRP3), and adapter protein apoptosis-associated speck-like protein (ASC) in heart tissues and cardiomyocytes. Real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) were applied for the detection of proinflammatory cytokines. We found that isofraxidin alleviated the severity of MI and produced a cardio-protective effect against OGD damage. Isofraxidin also decreased the overall and local inflammatory reaction in MI. Those effects were through the inhibition of the NLRP3 inflammasome. Taken together, we initially reported the cardio-protective and alleviative effect of isofraxidin on MI and uncovered its underlying mechanism related to the NLRP3 inflammasome inhibition.

Nur mit Berechtigung zugänglich

Raber, I., C.P. McCarthy, M. Vaduganathan, D.L. Bhatt, D.A. Wood, J.G.F. Cleland, R.S. Blumenthal, and J.W. McEvoy. 2019. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393 (10186): 2155–2167. https://doi.org/10.1016/S0140-6736(19)30541-0.CrossRefPubMed

Oder, D., M.S. Topp, and P. Nordbeck. 2019. Coronary B-cell lymphoma infiltration causing myocardial infarction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz538.

Koechlin, L., J. Boeddinghaus, T. Nestelberger, D. Wussler, J. Walter, F.J. Martin-Sanchez, N. Geigy, et al. 2019. Early diagnosis of myocardial infarction in patients with a history of coronary artery bypass grafting. Journal of the American College of Cardiology 74 (4): 587–589. https://doi.org/10.1016/j.jacc.2019.05.044.CrossRefPubMed

Lu, L., M. Liu, R. Sun, Y. Zheng, and P. Zhang. 2015. Myocardial infarction: Symptoms and treatments. Cell Biochemistry and Biophysics 72 (3): 865–867. https://doi.org/10.1007/s12013-015-0553-4.CrossRefPubMed

Kim, C.Y., J.H. Lee, S.Y. Jang, M.H. Bae, D.H. Yang, H.S. Park, Y. Cho, et al. 2019. Usefulness of calculation of cardiovascular risk factors to predict outcomes in patients with acute myocardial infarction. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2019.06.010.

Siri, S.R.A., B.M. Eliassen, B.K. Jacobsen, M. Melhus, A.R. Broderstad, V.L. Michalsen, and T. Braaten. 2019. Changes in conventional cardiovascular risk factors and the estimated 10-year risk of acute myocardial infarction or cerebral stroke in Sami and non-Sami populations in two population-based cross-sectional surveys: The SAMINOR study. BMJ Open 9 (7): e028939. https://doi.org/10.1136/bmjopen-2019-028939.CrossRefPubMedPubMedCentral

Sigirci, S., S.S. Yildiz, K. Keskin, G. Cetinkal, G. Aksan, A. Gurdal, S. Cetin, H. Kilci, and K.O. Kilickesmez. 2019. The predictive value of stress hyperglycemia on thrombus burden in nondiabetic patients with ST-segment elevation myocardial infarction. Blood Coagulation & Fibrinolysis. https://doi.org/10.1097/MBC.0000000000000832.

Rauf, A., M. Shah, D.M. Yellon, and S.M. Davidson. 2019. The role of caspase 1 in ischemia/reperfusion injury of the myocardium. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/FJC.0000000000000694.

Ibanez, B., A.H. Aletras, A.E. Arai, H. Arheden, J. Bax, C. Berry, C. Bucciarelli-Ducci, et al. 2019. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. Journal of the American College of Cardiology 74 (2): 238–256. https://doi.org/10.1016/j.jacc.2019.05.024.CrossRefPubMed

10.

Hu, J., C.X. Huang, P.P. Rao, G.Q. Cao, Y. Zhang, J.P. Zhou, L.Y. Zhu, M.X. Liu, and G.G. Zhang. 2019. MicroRNA-155 inhibition attenuates endoplasmic reticulum stress-induced cardiomyocyte apoptosis following myocardial infarction via reducing macrophage inflammation. European Journal of Pharmacology 857: 172449. https://doi.org/10.1016/j.ejphar.2019.172449.CrossRefPubMed

11.

Felger, J.C. 2018. Imaging the role of inflammation in mood and anxiety-related disorders. Current Neuropharmacology 16 (5): 533–558. https://doi.org/10.2174/1570159X15666171123201142.CrossRefPubMedPubMedCentral

12.

Ablasser, A., and Z.J. Chen. 2019. cGAS in action: Expanding roles in immunity and inflammation. Science 363 (6431). https://doi.org/10.1126/science.aat8657.

13.

Gong, T., W. Jiang, and R. Zhou. 2018. Control of inflammasome activation by phosphorylation. Trends in Biochemical Sciences 43 (9): 685–699. https://doi.org/10.1016/j.tibs.2018.06.008.CrossRefPubMed

14.

Shin, J.I., K.H. Lee, Y.H. Joo, J.M. Lee, J. Jeon, H.J. Jung, M. Shin, et al. 2019. Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review. J Autoimmun: 102299. https://doi.org/10.1016/j.jaut.2019.06.010.

15.

Winsor, N., C. Krustev, J. Bruce, D.J. Philpott, and S.E. Girardin. 2019. Canonical and noncanonical inflammasomes in intestinal epithelial cells. Cell Microbiol: e13079. https://doi.org/10.1111/cmi.13079.

16.

Henderson, J., S. Bhattacharyya, J. Varga, and S. O’Reilly. 2018. Targeting TLRs and the inflammasome in systemic sclerosis. Pharmacology & Therapeutics 192: 163–169. https://doi.org/10.1016/j.pharmthera.2018.08.003.CrossRef

17.

An, N., Y. Gao, Z. Si, H. Zhang, L. Wang, C. Tian, M. Yuan, et al. 2019. Regulatory mechanisms of the NLRP3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases. Frontiers in Immunology 10: 1592. https://doi.org/10.3389/fimmu.2019.01592.CrossRefPubMedPubMedCentral

18.

Kelley, N., D. Jeltema, Y. Duan, and Y. He. 2019. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences 20 (13). https://doi.org/10.3390/ijms20133328.

19.

Shao, B.Z., Z.Q. Xu, B.Z. Han, D.F. Su, and C. Liu. 2015. NLRP3 inflammasome and its inhibitors: A review. Frontiers in Pharmacology 6: 262. https://doi.org/10.3389/fphar.2015.00262.CrossRefPubMedPubMedCentral

20.

Toldo, S., and A. Abbate. 2018. The NLRP3 inflammasome in acute myocardial infarction. Nature Reviews. Cardiology 15 (4): 203–214. https://doi.org/10.1038/nrcardio.2017.161.CrossRefPubMed

21.

Gao, R., H. Shi, S. Chang, Y. Gao, X. Li, C. Lv, H. Yang, H. Xiang, J. Yang, L. Xu, and Y. Tang. 2019. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. International Immunopharmacology 74: 105575. https://doi.org/10.1016/j.intimp.2019.04.022.CrossRefPubMed

22.

Bian, Y., X. Li, P. Pang, X.L. Hu, S.T. Yu, Y.N. Liu, X. Li, N. Wang, J.H. Wang, W. Xiao, W.J. du, and B.F. Yang. 2019. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacologica Sinica: 1–8. https://doi.org/10.1038/s41401-019-0307-8.

23.

Yamazaki, T., and T. Tokiwa. 2010. Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits matrix metalloproteinase-7 expression and cell invasion of human hepatoma cells. Biological & Pharmaceutical Bulletin 33 (10): 1716–1722. https://doi.org/10.1248/bpb.33.1716.CrossRef

24.

Su, X., B. Liu, F. Gong, J. Yin, Q. Sun, Y. Gao, Z. Lv, and X. Wang. 2019. Isofraxidin attenuates IL-1beta-induced inflammatory response in human nucleus pulposus cells. Journal of Cellular Biochemistry 120 (8): 13302–13309. https://doi.org/10.1002/jcb.28604.CrossRefPubMed

25.

Li, J., X. Li, Z. Li, L. Zhang, Y. Liu, H. Ding, and S. Yin. 2017. Isofraxidin, a coumarin component improves high-fat diet induced hepatic lipid homeostasis disorder and macrophage inflammation in mice. Food & Function 8 (8): 2886–2896. https://doi.org/10.1039/c7fo00290d.CrossRef

26.

Lin, J., X. Li, W. Qi, Y. Yan, K. Chen, X. Xue, X. Xu, Z. Feng, and X. Pan. 2018. Isofraxidin inhibits interleukin-1beta induced inflammatory response in human osteoarthritis chondrocytes. International Immunopharmacology 64: 238–245. https://doi.org/10.1016/j.intimp.2018.09.003.CrossRefPubMed

27.

Liu, L., Q. Mu, W. Li, W. Xing, H. Zhang, T. Fan, H. Yao, and L. He. 2015. Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes. Immunobiology 220 (3): 406–413. https://doi.org/10.1016/j.imbio.2014.10.007.CrossRefPubMed

28.

Liao, Q., S. Qu, L.X. Tang, L.P. Li, D.F. He, C.Y. Zeng, and W.E. Wang. 2019. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis. Acta Pharmacologica Sinica 40: 1314–1321. https://doi.org/10.1038/s41401-019-0230-z.CrossRefPubMed

29.

Yu, W., G. Jin, J. Zhang, and W. Wei. 2019. Selective activation of cannabinoid receptor 2 attenuates myocardial infarction via suppressing NLRP3 inflammasome. Inflammation 42 (3): 904–914. https://doi.org/10.1007/s10753-018-0945-x.CrossRefPubMed

30.

Niu, X., W. Xing, W. Li, T. Fan, H. Hu, and Y. Li. 2012. Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-alpha production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway. International Immunopharmacology 14 (2): 164–171. https://doi.org/10.1016/j.intimp.2012.06.022.CrossRefPubMed

31.

Niu, X., Y. Wang, W. Li, Q. Mu, H. Li, H. Yao, and H. Zhang. 2015. Protective effects of isofraxidin against lipopolysaccharide-induced acute lung injury in mice. International Immunopharmacology 24 (2): 432–439. https://doi.org/10.1016/j.intimp.2014.12.041.CrossRefPubMed

32.

Takahashi, M. 2019. Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction. Biological & Pharmaceutical Bulletin 42 (4): 518–523. https://doi.org/10.1248/bpb.b18-00369.CrossRef

Titel: Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition
verfasst von: Guofan Chen
Xiaozheng Song
Dongming Lin
Peng Xu
Publikationsdatum: 08.01.2020
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 2/2020
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-019-01158-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal barrier and inhibiting inflammatory response

Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies

TNF Production in Activated RBL-2H3 Cells Requires Munc13-4

Sevoflurane Post-treatment Upregulated miR-203 Expression to Attenuate Cerebral Ischemia-Reperfusion-Induced Neuroinflammation by Targeting MyD88

Intra-subunit Disulfide Determines the Conversion and Structural Stability of CRP Isoforms

The Metabolic Reprogramming Profiles in the Liver Fibrosis of Mice Infected with Schistosoma japonicum

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Innere Medizin